In this issue, Espinoza and colleagues present the design of a 2-year randomized, double-blind, controlled, clinical trial testing whether 2,000 mg/day of metformin retards the advancement of frailty in prediabetic older adults. Demonstrating that any drug can deflect the progression of frailty would be a major milestone in geriatrics, but this study is also important within the larger frame of geroscience which hypothesizes that human health can be improved by directly targeting the biology of aging (1). Support for this hypothesis is found in studies of model organisms, which show that targeting these pathways in a variety of ways—including the administration of...

中文翻译：

---

测试Geroscience假设：早期。

在本期杂志中，Espinoza及其同事提出了一项为期2年的随机，双盲，对照，临床试验设计，以测试每天2,000 mg二甲双胍是否能延缓糖尿病前期成年人的体弱发育。证明任何药物都可以改变衰弱的进程将是老年医学的一个重要里程碑，但这项研究在更广泛的老年医学框架内也很重要，该框架假设可以通过直接针对衰老生物学来改善人类健康（1）。在模型生物的研究中发现了对这一假说的支持，该研究表明，以多种方式靶向这些途径，包括施用...